Abstract 74P
Background
Bone and soft-tissue sarcomas are rare malignant tumors comprising numerous histological subtypes. Novel effective therapies are still required. Recently, endoplasmic reticulum stress (ERs) responses have been suggested to be involved in the malignancy of various cancer types, prompting new studies focused on this area for the development of new therapies. Our previous proteomic study demonstrated an association between the ERs response and malignant behaviors in Ewing sarcomas (ESs). We also found that IRE1α inhibitors exert antitumor activity in ESs (Tanabe Y et al. Oncotarget 2017). To develop novel therapies for osteosarcomas (OSs), we performed comprehensive expression study of ERs genes using ER response arrays. Identified factors based on ER response arrays were investigated to elucidate these functional and antitumor activities using inhibitors of identified ERs in OSs.
Methods
To elucidate roles of main ER pathway in OS, we performed ER response arrays using OS cell lines. Based on results of ER response arrays, we conducted reverse transcription polymerase chain reaction (RT-PCR) and quantitative (q)-PCR to elucidate the expression of XBP1 and XBP1 splicing (XBP1s) variants in OS cell lines (143B, MG63, KHOS, KHOSR2, U2OS, U2OSR2) and surgical materials. Furthermore, we also performed XBP1 siRNA and inhibitor assays using several IRE1α-XBP1 inhibitors.
Results
ER response arrays using OS cell lines indicated some other pathways including XBP1 had high expressions in transcriptome levels. As we suggested XBP1played crucial roles in OS cell lines, we conducted functional assay focusing on XBP1 in OS cell lines. Expression of XBP1 was confirmed in OS cell lines and surgical materials by RT-PCR. The knockdown of XBP1 expression by siRNA inhibited the cell proliferation of the OS cell lines. Regarding inhibitor assays using IRE1α-XBP1 inhibitors, toyocamycin exerted a strong anti-tumor effect (IC50 <0.07 [0.04 to 0.07] μM) in the OS cell lines, despite SYO1, synovial sarcoma cell line had resistance of the inhibitor.
Conclusions
We found the association between the ER response and the tumor activity in OS. We also found that IRE1α-XBP1 inhibitors suppressed cell growths in OS.
Clinical trial identification
Editorial acknowledgement
This study was supported by Grant-in-Aid from the Japan Society for the Promotion of Science (JSPS) KAKENHI (Grant Number #19H03789 and 19K22694 to Y.S.; 19K16753 to K.A.; 18K15329 to T.O.; # 18K16634 to Y.K.).
Legal entity responsible for the study
The authors.
Funding
This study was supported by Grant-in-Aid from the Japan Society for the Promotion of Science (JSPS) KAKENHI (Grant Number #19H03789 and 19K22694 to Y.S.; 19K16753 to K.A.; 18K15329 to T.O.; # 18K16634 to Y.K.).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
184P - Development and external validation of a nomogram to predict recurrence-free survival after R0 resection for stage II/III gastric adenocarcinoma: An international multicenter study
Presenter: Bin-Bin Xu
Session: e-Poster Display Session
185P - Effect of sarcopenia on short- and long-term outcomes of patients with gastric neuroendocrine tumour after radical surgery: Results from a large, two-institutional series
Presenter: Ling-Qian Wang
Session: e-Poster Display Session
186P - Characterization of the gastroenteropancreatic neuroendocrine tumour patient journey
Presenter: George Fisher Jr
Session: e-Poster Display Session
187P - More is not always better: A multicenter study in lymphadenectomy during gastrectomy for gastric neuroendocrine carcinoma
Presenter: Qi-Yue Chen
Session: e-Poster Display Session
188P - The impact of sarcopenia on chemotherapy toxicity and survival rate among pancreatic cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Billy Susanto
Session: e-Poster Display Session
189P - Prognostic value of inflammation-based score for patients treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP)
Presenter: Takahiro Yamamura
Session: e-Poster Display Session
190P - Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)
Presenter: Joon Oh Park
Session: e-Poster Display Session
191P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study
Presenter: Andrew Dean
Session: e-Poster Display Session
192P - A multicenter crossover analysis of first and second-line FOLFIRINOX or gemcitabine plus nab-paclitaxel administered to pancreatic cancer patients: Results from the NAPOLEON study
Presenter: Kenta Nio
Session: e-Poster Display Session
193P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Exploratory survival analyses by change in post treatment CA 19-9
Presenter: Andrew Dean
Session: e-Poster Display Session